Overview

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.

Phase:

Phase 1

Details

Lead Sponsor:

Ronald Buckanovich
University of Michigan Cancer Center

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel